Bozicevic, Field & Francis LLP
Dosing parameters for CD47 targeting therapies to hematologic malignancies
Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.
Forty Seven, Inc. The Board of Trustees of the Leland Stanford Junior University
C A A A C C A A C A
C07K A61P A61K A61K C07K C07K A61K A61K C07K A61K
inventional inventional inventional inventional additional additional additional inventional additional additional
Jens-Peter Irving L. Jie Ravindra Mark P.
Volkmer Weissman Liu Majeti Chao